Clinically, in patients with pancreatic cancer, high serum levels of IL-6 correlate with poor prognosis (Lesina et al. 2014), and Oncostatin M (OSM) was overexpressed in the sera of patients with PDAC (Torres et al. 2014). The gene discussed is OSM; the disease is familial pancreatic carcinoma.